Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.38 -0.01 (-1.28%)
As of 10/2/2026 01:59 PM Eastern
Compare

MDNA vs. COV, SCYB, COM, NVH, and HBP

Should you buy Medicenna Therapeutics stock or one of its competitors? Medicenna Therapeutics's main competitors and comparable companies include Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Helix BioPharma (HBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to Covalon Technologies?

Covalon Technologies (CVE:COV) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Covalon Technologies has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$34.35M3.20C$2.39MC$0.1624.88
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Covalon Technologies has a net margin of 12.78% compared to Medicenna Therapeutics' net margin of -533,640.00%. Covalon Technologies' return on equity of 15.04% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Covalon Technologies12.78% 15.04% -3.25%
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

0.2% of Covalon Technologies shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 48.7% of Covalon Technologies shares are held by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Covalon Technologies and Covalon Technologies both had 2 articles in the media. Medicenna Therapeutics' average media sentiment score of 0.74 beat Covalon Technologies' score of 0.51 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Covalon Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medicenna Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Covalon Technologies has a beta of 1.397953, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 3.001413, meaning that its stock price is 200% more volatile than the broader market.

Summary

Covalon Technologies beats Medicenna Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Medicenna Therapeutics (TSE:MDNA) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Scythian Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Scythian Biosciences. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Scythian Biosciences. Medicenna Therapeutics' average media sentiment score of 0.74 beat Scythian Biosciences' score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Positive
Scythian Biosciences Neutral

Summary

Medicenna Therapeutics beats Scythian Biosciences on 4 of the 7 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

In the previous week, Medicenna Therapeutics had 2 more articles in the media than 138267 (COM.TO). MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for 138267 (COM.TO). Medicenna Therapeutics' average media sentiment score of 0.74 beat 138267 (COM.TO)'s score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
138267 (COM.TO) Neutral
Medicenna Therapeutics Positive

Summary

Medicenna Therapeutics beats 138267 (COM.TO) on 4 of the 7 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Medicenna Therapeutics (TSE:MDNA) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Novoheart N/A N/A N/A

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Novoheart. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Novoheart. Medicenna Therapeutics' average media sentiment score of 0.74 beat Novoheart's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Positive
Novoheart Neutral

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Helix BioPharma?

Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Medicenna Therapeutics has a beta of 3.001413, suggesting that its share price is 200% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.722962, suggesting that its share price is 28% less volatile than the broader market.

In the previous week, Medicenna Therapeutics and Medicenna Therapeutics both had 2 articles in the media. Medicenna Therapeutics' average media sentiment score of 0.74 beat Helix BioPharma's score of 0.31 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medicenna Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Helix BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -21.54% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Helix BioPharma N/A -21.54%-279.98%

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Medicenna Therapeutics beats Helix BioPharma on 7 of the 10 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$36.00MC$3.86BC$7.15BC$12.68B
Dividend YieldN/A3.65%2.54%6.33%
P/E Ratio-1.7513.06275.6739.33
Price / SalesN/A1,292.17656.669.16
Price / Cash1.15123.3978.8782.29
Price / Book19.9416.6310.934.61
Net Income-C$25.98M-C$22.71MC$3.51BC$299.09M
7 Day PerformanceN/A-2.99%-2.00%-1.15%
1 Month Performance-18.09%-10.81%-6.19%-2.92%
1 Year Performance-61.11%19.19%8.03%16.25%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.39
-1.3%		N/A-61.1%C$36.00MN/AN/A20
COV
Covalon Technologies
N/AC$4.24
+4.2%		N/A+88.6%C$117.10MC$34.35M26.50N/A
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
Larry's Three-Step Strategy Revealed at The Dollar Trap Summit
Larry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...
Brownstone Research | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel